Research - Just as investors were getting comfortable with bluebird bio’s (BLUE) most recent disappointment, it’s happened again. Today at the American Society of Hematology’s annual meeting, bluebird revealed updated results from HGB-206, the company’s small phase 1/2 study dedicated exclusively to treating Sickle Cell Disease patients with LentiGlobin.
Premium: Read NowResearch - Street Insider reported on Friday afternoon that Merck (MRK) plans to make an offer for Relypsa (RLYP). FT Alphaville is confirming with a similar story, citing GlaxoSmithKline … Continue Reading
Premium: Read NowResearch - Cellectis/treating physicians will discuss the first-in-human experience with UCART19, the company's allogeneic CD-19 targeted CAR-T asset, at ASH. And, they may be able to discuss results in more than one patient.
Premium: Read NowResearch - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read NowResearch - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.
Premium: Read NowResearch - AstraZeneca (AZN) will buy ZS Pharma (ZSPH) for $2.7 billion in cash, or $90 per share - a 42% premium to yesterday's close. Recall that Relypsa (RLYP) and its Veltassa (patiromer) are neck and neck as new entrants to the hyperkalemia market.
Read NowResearch - ASH 2015 abstracts are available publicly this morning (browse them here), and biotech had a rough morning.
Premium: Read Now
